Stem definition | Drug id | CAS RN |
---|---|---|
2561 | 10540-29-1 |
Dose | Unit | Route |
---|---|---|
20 | mg | O |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 0.50 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 0.50 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 1.18 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Date | Agency | Company | Orphan |
---|---|---|---|
Dec. 30, 1977 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Metastases to bone | 1434.74 | 11.37 | 517 | 33872 | 17478 | 50553257 |
Malignant neoplasm progression | 1369.95 | 11.37 | 742 | 33647 | 67382 | 50503353 |
Metastases to liver | 793.98 | 11.37 | 348 | 34041 | 19756 | 50550979 |
Metastases to lung | 474.91 | 11.37 | 203 | 34186 | 10817 | 50559918 |
Metastases to lymph nodes | 428.28 | 11.37 | 166 | 34223 | 6858 | 50563877 |
Breast cancer recurrent | 389.86 | 11.37 | 132 | 34257 | 3676 | 50567059 |
Disease progression | 369.21 | 11.37 | 387 | 34002 | 95479 | 50475256 |
Breast cancer metastatic | 362.80 | 11.37 | 165 | 34224 | 10199 | 50560536 |
Neoplasm progression | 342.12 | 11.37 | 225 | 34164 | 28932 | 50541803 |
Osteonecrosis of jaw | 232.68 | 11.37 | 186 | 34203 | 32340 | 50538395 |
Breast cancer | 205.18 | 11.37 | 195 | 34194 | 42695 | 50528040 |
Metastasis | 183.17 | 11.37 | 79 | 34310 | 4296 | 50566439 |
Uterine polyp | 160.39 | 11.37 | 56 | 34333 | 1712 | 50569023 |
Metastases to central nervous system | 159.50 | 11.37 | 98 | 34291 | 11184 | 50559551 |
Metastases to spine | 144.94 | 11.37 | 59 | 34330 | 2772 | 50567963 |
Hot flush | 143.08 | 11.37 | 163 | 34226 | 44006 | 50526729 |
Endometrial hyperplasia | 139.86 | 11.37 | 41 | 34348 | 701 | 50570034 |
Osteonecrosis | 136.46 | 11.37 | 117 | 34272 | 22400 | 50548335 |
Bone disorder | 133.55 | 11.37 | 107 | 34282 | 18645 | 50552090 |
Second primary malignancy | 129.28 | 11.37 | 72 | 34317 | 6842 | 50563893 |
PIK3CA-activated mutation | 119.26 | 11.37 | 37 | 34352 | 773 | 50569962 |
Bone lesion | 113.83 | 11.37 | 60 | 34329 | 5110 | 50565625 |
Hormone receptor positive breast cancer | 110.14 | 11.37 | 31 | 34358 | 455 | 50570280 |
Acute myeloid leukaemia | 109.44 | 11.37 | 87 | 34302 | 14987 | 50555748 |
Drug ineffective | 106.38 | 11.37 | 252 | 34137 | 819081 | 49751654 |
Sarcoma uterus | 101.35 | 11.37 | 18 | 34371 | 17 | 50570718 |
Tumour marker increased | 100.29 | 11.37 | 50 | 34339 | 3790 | 50566945 |
Endometrial hypertrophy | 97.33 | 11.37 | 25 | 34364 | 253 | 50570482 |
Metastases to pleura | 94.52 | 11.37 | 35 | 34354 | 1271 | 50569464 |
Neuropathy peripheral | 94.15 | 11.37 | 205 | 34184 | 96552 | 50474183 |
Hepatic lesion | 86.78 | 11.37 | 46 | 34343 | 3962 | 50566773 |
Contraindicated product administered | 81.32 | 11.37 | 5 | 34384 | 148953 | 50421782 |
Hysteroscopy | 80.50 | 11.37 | 15 | 34374 | 23 | 50570712 |
Metastases to the mediastinum | 79.99 | 11.37 | 24 | 34365 | 446 | 50570289 |
Palmar-plantar erythrodysaesthesia syndrome | 78.70 | 11.37 | 82 | 34307 | 20016 | 50550719 |
Osteolysis | 77.92 | 11.37 | 37 | 34352 | 2520 | 50568215 |
Rheumatoid arthritis | 77.36 | 11.37 | 21 | 34368 | 202529 | 50368206 |
Pseudocirrhosis | 77.12 | 11.37 | 25 | 34364 | 605 | 50570130 |
Endometrial cancer | 76.65 | 11.37 | 38 | 34351 | 2845 | 50567890 |
Systemic lupus erythematosus | 75.93 | 11.37 | 5 | 34384 | 140617 | 50430118 |
Metastases to peritoneum | 74.31 | 11.37 | 37 | 34352 | 2796 | 50567939 |
Device related thrombosis | 72.99 | 11.37 | 29 | 34360 | 1278 | 50569457 |
Joint swelling | 71.27 | 11.37 | 39 | 34350 | 245247 | 50325488 |
Bone pain | 70.46 | 11.37 | 120 | 34269 | 47109 | 50523626 |
Death | 69.87 | 11.37 | 418 | 33971 | 324961 | 50245774 |
Tonsillar disorder | 68.60 | 11.37 | 26 | 34363 | 1008 | 50569727 |
Metastases to skin | 67.99 | 11.37 | 28 | 34361 | 1355 | 50569380 |
Recurrent cancer | 67.92 | 11.37 | 30 | 34359 | 1727 | 50569008 |
Neutropenia | 66.17 | 11.37 | 236 | 34153 | 147729 | 50423006 |
Glossodynia | 65.82 | 11.37 | 3 | 34386 | 115566 | 50455169 |
Endometrial atrophy | 65.64 | 11.37 | 14 | 34375 | 56 | 50570679 |
Therapeutic product effect decreased | 64.98 | 11.37 | 8 | 34381 | 136042 | 50434693 |
Blood uric acid decreased | 63.39 | 11.37 | 22 | 34367 | 660 | 50570075 |
Nail disorder | 59.93 | 11.37 | 51 | 34338 | 9657 | 50561078 |
Synovitis | 59.85 | 11.37 | 7 | 34382 | 123858 | 50446877 |
Carbohydrate antigen 15-3 increased | 59.35 | 11.37 | 24 | 34365 | 1108 | 50569627 |
Pleural effusion | 59.07 | 11.37 | 154 | 34235 | 81300 | 50489435 |
Uterine cancer | 58.66 | 11.37 | 35 | 34354 | 3785 | 50566950 |
Lymphoedema | 58.53 | 11.37 | 49 | 34340 | 9073 | 50561662 |
Lymphadenopathy | 57.93 | 11.37 | 91 | 34298 | 33408 | 50537327 |
Acute promyelocytic leukaemia | 57.82 | 11.37 | 22 | 34367 | 862 | 50569873 |
Nasal disorder | 57.18 | 11.37 | 29 | 34360 | 2279 | 50568456 |
Endocervical curettage | 56.65 | 11.37 | 9 | 34380 | 0 | 50570735 |
Eosinophil percentage increased | 56.10 | 11.37 | 22 | 34367 | 936 | 50569799 |
Ovarian hyperstimulation syndrome | 55.83 | 11.37 | 32 | 34357 | 3212 | 50567523 |
Metastases to pelvis | 55.12 | 11.37 | 17 | 34372 | 348 | 50570387 |
Ascites | 53.33 | 11.37 | 91 | 34298 | 35770 | 50534965 |
Excessive eye blinking | 52.86 | 11.37 | 21 | 34368 | 925 | 50569810 |
Abdominal discomfort | 51.40 | 11.37 | 49 | 34340 | 231592 | 50339143 |
Breast mass | 50.65 | 11.37 | 39 | 34350 | 6410 | 50564325 |
Pulmonary mass | 50.59 | 11.37 | 63 | 34326 | 18642 | 50552093 |
Metastases to thorax | 49.46 | 11.37 | 14 | 34375 | 210 | 50570525 |
Maternal exposure during pregnancy | 48.46 | 11.37 | 24 | 34365 | 159754 | 50410981 |
Recall phenomenon | 48.09 | 11.37 | 17 | 34372 | 539 | 50570196 |
Tooth extraction | 46.69 | 11.37 | 43 | 34346 | 9032 | 50561703 |
Endometriosis | 46.66 | 11.37 | 31 | 34358 | 4044 | 50566691 |
Breast cancer female | 46.40 | 11.37 | 38 | 34351 | 6824 | 50563911 |
Wound | 46.39 | 11.37 | 8 | 34381 | 105786 | 50464949 |
Completed suicide | 46.14 | 11.37 | 16 | 34373 | 131873 | 50438862 |
Hepatic enzyme increased | 45.81 | 11.37 | 18 | 34371 | 137362 | 50433373 |
Disease recurrence | 45.53 | 11.37 | 62 | 34327 | 20019 | 50550716 |
Lymphangiosis carcinomatosa | 44.88 | 11.37 | 20 | 34369 | 1176 | 50569559 |
Ovarian cancer | 44.56 | 11.37 | 33 | 34356 | 5116 | 50565619 |
Left ventricular dilatation | 44.44 | 11.37 | 15 | 34374 | 413 | 50570322 |
Peritoneal disorder | 43.77 | 11.37 | 15 | 34374 | 433 | 50570302 |
Dural arteriovenous fistula | 43.45 | 11.37 | 8 | 34381 | 11 | 50570724 |
Metastases to ovary | 43.29 | 11.37 | 14 | 34375 | 336 | 50570399 |
Vitreous detachment | 42.87 | 11.37 | 22 | 34367 | 1772 | 50568963 |
Metastases to chest wall | 42.82 | 11.37 | 15 | 34374 | 463 | 50570272 |
Retinopathy | 42.04 | 11.37 | 25 | 34364 | 2687 | 50568048 |
Hypertriglyceridaemia | 40.51 | 11.37 | 32 | 34357 | 5459 | 50565276 |
Ejection fraction decreased | 40.21 | 11.37 | 56 | 34333 | 18464 | 50552271 |
Haematotoxicity | 39.83 | 11.37 | 37 | 34352 | 7858 | 50562877 |
Polyneuropathy | 39.64 | 11.37 | 45 | 34344 | 12086 | 50558649 |
Metastatic neoplasm | 39.26 | 11.37 | 27 | 34362 | 3727 | 50567008 |
Cerebral venous thrombosis | 39.17 | 11.37 | 21 | 34368 | 1850 | 50568885 |
Sinusitis | 39.09 | 11.37 | 35 | 34354 | 170523 | 50400212 |
Lymphadenopathy mediastinal | 38.54 | 11.37 | 23 | 34366 | 2488 | 50568247 |
Onycholysis | 36.78 | 11.37 | 18 | 34371 | 1310 | 50569425 |
Pneumonia | 36.69 | 11.37 | 133 | 34256 | 378268 | 50192467 |
Metastases to muscle | 36.44 | 11.37 | 10 | 34379 | 133 | 50570602 |
Bronchomalacia | 36.34 | 11.37 | 11 | 34378 | 211 | 50570524 |
Vulvovaginal dryness | 35.84 | 11.37 | 21 | 34368 | 2196 | 50568539 |
Hypersensitivity | 35.64 | 11.37 | 57 | 34332 | 215104 | 50355631 |
Exposure during pregnancy | 35.46 | 11.37 | 19 | 34370 | 120996 | 50449739 |
Pulmonary embolism | 35.44 | 11.37 | 150 | 34239 | 101554 | 50469181 |
Swelling | 35.40 | 11.37 | 51 | 34338 | 200821 | 50369914 |
BRAF gene mutation | 34.97 | 11.37 | 8 | 34381 | 47 | 50570688 |
Spinal cord compression | 34.89 | 11.37 | 25 | 34364 | 3684 | 50567051 |
Rash | 34.81 | 11.37 | 166 | 34223 | 437305 | 50133430 |
Endometrial disorder | 34.75 | 11.37 | 14 | 34375 | 640 | 50570095 |
Portal hypertension | 34.54 | 11.37 | 24 | 34365 | 3368 | 50567367 |
Endometrial thickening | 34.21 | 11.37 | 11 | 34378 | 259 | 50570476 |
Exposed bone in jaw | 33.76 | 11.37 | 22 | 34367 | 2778 | 50567957 |
Drug hypersensitivity | 33.26 | 11.37 | 76 | 34313 | 250934 | 50319801 |
Condition aggravated | 33.21 | 11.37 | 98 | 34291 | 296960 | 50273775 |
Blood creatinine decreased | 32.48 | 11.37 | 27 | 34362 | 4949 | 50565786 |
Hepatic cirrhosis | 32.13 | 11.37 | 49 | 34340 | 17528 | 50553207 |
Bone cancer metastatic | 32.04 | 11.37 | 9 | 34380 | 131 | 50570604 |
Metastases to uterus | 31.89 | 11.37 | 8 | 34381 | 73 | 50570662 |
Treatment failure | 31.82 | 11.37 | 28 | 34361 | 137609 | 50433126 |
Hypertransaminasaemia | 30.93 | 11.37 | 23 | 34366 | 3588 | 50567147 |
Infusion related reaction | 30.92 | 11.37 | 42 | 34347 | 169515 | 50401220 |
Uterine leiomyoma | 30.54 | 11.37 | 32 | 34357 | 7859 | 50562876 |
Pleural disorder | 30.05 | 11.37 | 12 | 34377 | 536 | 50570199 |
Hydrothorax | 29.94 | 11.37 | 13 | 34376 | 718 | 50570017 |
Menopause | 29.82 | 11.37 | 19 | 34370 | 2308 | 50568427 |
Malignant pleural effusion | 29.80 | 11.37 | 19 | 34370 | 2311 | 50568424 |
Menopausal disorder | 29.54 | 11.37 | 7 | 34382 | 49 | 50570686 |
Tumour invasion | 29.53 | 11.37 | 8 | 34381 | 101 | 50570634 |
Osteosclerosis | 29.51 | 11.37 | 22 | 34367 | 3445 | 50567290 |
Product use issue | 29.35 | 11.37 | 35 | 34354 | 149440 | 50421295 |
Cervical polyp | 28.74 | 11.37 | 9 | 34380 | 194 | 50570541 |
Adenocarcinoma | 28.71 | 11.37 | 19 | 34370 | 2462 | 50568273 |
Invasive ductal breast carcinoma | 28.43 | 11.37 | 27 | 34362 | 5894 | 50564841 |
Nasopharyngitis | 28.41 | 11.37 | 55 | 34334 | 192872 | 50377863 |
Acquired gene mutation | 28.34 | 11.37 | 13 | 34376 | 818 | 50569917 |
Adnexa uteri mass | 27.98 | 11.37 | 11 | 34378 | 471 | 50570264 |
Radiation skin injury | 27.87 | 11.37 | 13 | 34376 | 850 | 50569885 |
Radiation necrosis | 27.82 | 11.37 | 10 | 34379 | 333 | 50570402 |
Left ventricular dysfunction | 27.79 | 11.37 | 35 | 34354 | 10471 | 50560264 |
Uterine dilation and curettage | 27.74 | 11.37 | 13 | 34376 | 859 | 50569876 |
Cardiac cirrhosis | 27.61 | 11.37 | 8 | 34381 | 131 | 50570604 |
Neoplasm recurrence | 27.07 | 11.37 | 18 | 34371 | 2351 | 50568384 |
Osteitis condensans | 26.88 | 11.37 | 6 | 34383 | 31 | 50570704 |
Pericarditis | 26.74 | 11.37 | 10 | 34379 | 78679 | 50492056 |
Injection site pain | 26.38 | 11.37 | 22 | 34367 | 111002 | 50459733 |
Oestradiol abnormal | 26.26 | 11.37 | 6 | 34383 | 35 | 50570700 |
Mucosal inflammation | 26.17 | 11.37 | 73 | 34316 | 40069 | 50530666 |
RET gene mutation | 25.99 | 11.37 | 5 | 34384 | 10 | 50570725 |
Jaw operation | 25.97 | 11.37 | 12 | 34377 | 768 | 50569967 |
Gastrointestinal toxicity | 25.71 | 11.37 | 23 | 34366 | 4654 | 50566081 |
Breast cancer stage IV | 25.43 | 11.37 | 11 | 34378 | 602 | 50570133 |
Porphyria non-acute | 25.38 | 11.37 | 9 | 34380 | 288 | 50570447 |
Tympanic membrane disorder | 25.27 | 11.37 | 8 | 34381 | 179 | 50570556 |
Radiation pneumonitis | 25.22 | 11.37 | 14 | 34375 | 1321 | 50569414 |
Drug abuse | 25.21 | 11.37 | 5 | 34384 | 59841 | 50510894 |
Metastases to stomach | 25.02 | 11.37 | 8 | 34381 | 185 | 50570550 |
Bone sequestrum | 24.81 | 11.37 | 14 | 34375 | 1364 | 50569371 |
Malignant neoplasm of pleura | 24.73 | 11.37 | 6 | 34383 | 47 | 50570688 |
Mucosal toxicity | 24.67 | 11.37 | 9 | 34380 | 313 | 50570422 |
Pain in jaw | 24.18 | 11.37 | 69 | 34320 | 38359 | 50532376 |
Gingival bleeding | 24.15 | 11.37 | 34 | 34355 | 11319 | 50559416 |
Arthropathy | 24.14 | 11.37 | 44 | 34345 | 157862 | 50412873 |
Tumour marker decreased | 23.61 | 11.37 | 6 | 34383 | 58 | 50570677 |
Actinomycosis | 23.49 | 11.37 | 12 | 34377 | 957 | 50569778 |
Pain | 23.15 | 11.37 | 267 | 34122 | 578636 | 49992099 |
Deprescribing error | 23.06 | 11.37 | 5 | 34384 | 22 | 50570713 |
Jaw disorder | 22.71 | 11.37 | 22 | 34367 | 4921 | 50565814 |
Vaginal haemorrhage | 22.69 | 11.37 | 51 | 34338 | 24500 | 50546235 |
Leiomyoma | 22.60 | 11.37 | 9 | 34380 | 399 | 50570336 |
Pathological fracture | 22.60 | 11.37 | 27 | 34362 | 7655 | 50563080 |
Central nervous system lesion | 22.58 | 11.37 | 30 | 34359 | 9459 | 50561276 |
Maculopathy | 22.56 | 11.37 | 15 | 34374 | 1959 | 50568776 |
Sequestrectomy | 22.42 | 11.37 | 11 | 34378 | 805 | 50569930 |
Dental operation | 22.13 | 11.37 | 12 | 34377 | 1081 | 50569654 |
Metastases to breast | 22.02 | 11.37 | 8 | 34381 | 275 | 50570460 |
Hysterectomy | 22.02 | 11.37 | 27 | 34362 | 7863 | 50562872 |
Metastases to bone marrow | 21.99 | 11.37 | 8 | 34381 | 276 | 50570459 |
Skin hypopigmentation | 21.92 | 11.37 | 10 | 34379 | 621 | 50570114 |
Eastern Cooperative Oncology Group performance status worsened | 21.82 | 11.37 | 10 | 34379 | 628 | 50570107 |
Hepatic steatosis | 21.81 | 11.37 | 50 | 34339 | 24334 | 50546401 |
Fibrous histiocytoma | 21.57 | 11.37 | 9 | 34380 | 450 | 50570285 |
Malignant neoplasm of choroid | 21.52 | 11.37 | 4 | 34385 | 6 | 50570729 |
Toothache | 21.42 | 11.37 | 40 | 34349 | 16854 | 50553881 |
HER2 positive breast cancer | 21.28 | 11.37 | 8 | 34381 | 303 | 50570432 |
Invasive lobular breast carcinoma | 21.28 | 11.37 | 10 | 34379 | 665 | 50570070 |
Abdominal lymphadenopathy | 21.20 | 11.37 | 10 | 34379 | 671 | 50570064 |
Atrophic vulvovaginitis | 20.38 | 11.37 | 13 | 34376 | 1583 | 50569152 |
Jaundice | 20.20 | 11.37 | 51 | 34338 | 26378 | 50544357 |
Osteomyelitis | 20.17 | 11.37 | 46 | 34343 | 22307 | 50548428 |
Infection | 20.07 | 11.37 | 56 | 34333 | 172898 | 50397837 |
Injection site extravasation | 19.86 | 11.37 | 25 | 34364 | 7476 | 50563259 |
Discomfort | 19.59 | 11.37 | 27 | 34362 | 108353 | 50462382 |
Neoplasm | 19.38 | 11.37 | 22 | 34367 | 5906 | 50564829 |
Meningeal disorder | 19.26 | 11.37 | 7 | 34382 | 241 | 50570494 |
Therapy partial responder | 19.11 | 11.37 | 23 | 34366 | 6568 | 50564167 |
Polypectomy | 19.00 | 11.37 | 9 | 34380 | 609 | 50570126 |
Congestive cardiomyopathy | 18.93 | 11.37 | 21 | 34368 | 5497 | 50565238 |
Amenorrhoea | 18.93 | 11.37 | 26 | 34363 | 8458 | 50562277 |
Pulmonary radiation injury | 18.88 | 11.37 | 3 | 34386 | 0 | 50570735 |
Uterine polypectomy | 18.88 | 11.37 | 3 | 34386 | 0 | 50570735 |
Weight increased | 18.84 | 11.37 | 72 | 34317 | 201819 | 50368916 |
Ovarian cyst | 18.83 | 11.37 | 34 | 34355 | 13962 | 50556773 |
Carcinoembryonic antigen increased | 18.80 | 11.37 | 12 | 34377 | 1462 | 50569273 |
Portal vein thrombosis | 18.75 | 11.37 | 14 | 34375 | 2198 | 50568537 |
Oestrogen receptor assay positive | 18.54 | 11.37 | 8 | 34381 | 435 | 50570300 |
Neutrophilia | 18.51 | 11.37 | 17 | 34372 | 3558 | 50567177 |
Adenomyosis | 18.19 | 11.37 | 8 | 34381 | 456 | 50570279 |
Product dose omission issue | 18.18 | 11.37 | 64 | 34325 | 183774 | 50386961 |
Myelodysplastic syndrome | 18.16 | 11.37 | 35 | 34354 | 15097 | 50555638 |
Gastrointestinal haemorrhage | 18.07 | 11.37 | 14 | 34375 | 73307 | 50497428 |
Breath odour | 18.04 | 11.37 | 11 | 34378 | 1237 | 50569498 |
Activated PI3 kinase delta syndrome | 18.03 | 11.37 | 4 | 34385 | 20 | 50570715 |
Oophorectomy | 17.97 | 11.37 | 8 | 34381 | 469 | 50570266 |
Lymphangioleiomyomatosis | 17.96 | 11.37 | 6 | 34383 | 160 | 50570575 |
Cardiotoxicity | 17.94 | 11.37 | 23 | 34366 | 7004 | 50563731 |
Toxicity to various agents | 17.82 | 11.37 | 79 | 34310 | 212420 | 50358315 |
Disturbance in attention | 17.72 | 11.37 | 54 | 34335 | 31132 | 50539603 |
Peripheral swelling | 17.61 | 11.37 | 76 | 34313 | 205860 | 50364875 |
Breast disorder | 17.59 | 11.37 | 13 | 34376 | 2009 | 50568726 |
Aeromonas infection | 17.54 | 11.37 | 5 | 34384 | 77 | 50570658 |
Breast neoplasm | 17.53 | 11.37 | 11 | 34378 | 1302 | 50569433 |
Corneal degeneration | 17.48 | 11.37 | 5 | 34384 | 78 | 50570657 |
Menopausal symptoms | 17.47 | 11.37 | 13 | 34376 | 2030 | 50568705 |
Macular hole | 17.43 | 11.37 | 9 | 34380 | 734 | 50570001 |
Somnolence | 17.38 | 11.37 | 51 | 34338 | 154934 | 50415801 |
Therapeutic product effect incomplete | 17.35 | 11.37 | 22 | 34367 | 91493 | 50479242 |
Corneal graft rejection | 17.14 | 11.37 | 4 | 34385 | 26 | 50570709 |
Paraneoplastic syndrome | 17.12 | 11.37 | 8 | 34381 | 525 | 50570210 |
Headache | 17.11 | 11.37 | 242 | 34147 | 506293 | 50064442 |
Respiratory tract inflammation | 17.02 | 11.37 | 8 | 34381 | 532 | 50570203 |
Ventricular hypokinesia | 16.96 | 11.37 | 17 | 34372 | 3963 | 50566772 |
Pruritus | 16.91 | 11.37 | 118 | 34271 | 283450 | 50287285 |
Oxygen saturation decreased | 16.80 | 11.37 | 15 | 34374 | 73233 | 50497502 |
Cortisol increased | 16.72 | 11.37 | 7 | 34382 | 353 | 50570382 |
Intentional overdose | 16.63 | 11.37 | 11 | 34378 | 62493 | 50508242 |
Diabetic hyperosmolar coma | 16.56 | 11.37 | 7 | 34382 | 362 | 50570373 |
Loss of personal independence in daily activities | 16.49 | 11.37 | 14 | 34375 | 70036 | 50500699 |
Contusion | 16.49 | 11.37 | 32 | 34357 | 112151 | 50458584 |
Invasive breast carcinoma | 16.41 | 11.37 | 8 | 34381 | 577 | 50570158 |
Acute lymphocytic leukaemia | 16.40 | 11.37 | 13 | 34376 | 2228 | 50568507 |
Atrial thrombosis | 16.34 | 11.37 | 11 | 34378 | 1466 | 50569269 |
Sensory loss | 16.20 | 11.37 | 23 | 34366 | 7715 | 50563020 |
Performance status decreased | 16.17 | 11.37 | 15 | 34374 | 3180 | 50567555 |
Debridement | 16.05 | 11.37 | 10 | 34379 | 1169 | 50569566 |
Gingivitis | 15.77 | 11.37 | 22 | 34367 | 7262 | 50563473 |
Myalgia | 15.75 | 11.37 | 141 | 34248 | 124178 | 50446557 |
Libido decreased | 15.73 | 11.37 | 13 | 34376 | 2363 | 50568372 |
Acarodermatitis | 15.56 | 11.37 | 9 | 34380 | 919 | 50569816 |
Hypotension | 15.54 | 11.37 | 95 | 34294 | 235374 | 50335361 |
Arteriovenous malformation | 15.45 | 11.37 | 10 | 34379 | 1248 | 50569487 |
Liver scan abnormal | 15.44 | 11.37 | 4 | 34385 | 42 | 50570693 |
Oral pustule | 15.44 | 11.37 | 4 | 34385 | 42 | 50570693 |
Salpingitis | 15.42 | 11.37 | 6 | 34383 | 250 | 50570485 |
Intermenstrual bleeding | 15.38 | 11.37 | 21 | 34368 | 6793 | 50563942 |
Uterine haemorrhage | 15.32 | 11.37 | 15 | 34374 | 3400 | 50567335 |
Septic shock | 15.29 | 11.37 | 10 | 34379 | 57165 | 50513570 |
Rapidly progressive osteoarthritis | 15.28 | 11.37 | 3 | 34386 | 7 | 50570728 |
Respiratory tract oedema | 15.25 | 11.37 | 7 | 34382 | 441 | 50570294 |
Metastases to eye | 15.19 | 11.37 | 5 | 34384 | 127 | 50570608 |
Blood alkaline phosphatase increased | 15.18 | 11.37 | 58 | 34331 | 37468 | 50533267 |
Central nervous system infection | 15.13 | 11.37 | 8 | 34381 | 685 | 50570050 |
Acute kidney injury | 15.06 | 11.37 | 92 | 34297 | 227966 | 50342769 |
Blood bilirubin increased | 15.06 | 11.37 | 52 | 34337 | 31986 | 50538749 |
Paraesthesia | 15.04 | 11.37 | 136 | 34253 | 120107 | 50450628 |
Urticaria | 14.99 | 11.37 | 42 | 34347 | 129519 | 50441216 |
Rhabdomyolysis | 14.96 | 11.37 | 4 | 34385 | 39023 | 50531712 |
Deafness | 14.95 | 11.37 | 33 | 34356 | 15658 | 50555077 |
Vertebral lesion | 14.92 | 11.37 | 7 | 34382 | 464 | 50570271 |
Haemangioma of liver | 14.87 | 11.37 | 9 | 34380 | 999 | 50569736 |
Chronic hepatic failure | 14.78 | 11.37 | 7 | 34382 | 474 | 50570261 |
Periodontitis | 14.74 | 11.37 | 14 | 34375 | 3055 | 50567680 |
Blood follicle stimulating hormone decreased | 14.73 | 11.37 | 3 | 34386 | 9 | 50570726 |
Oesophageal varices haemorrhage | 14.69 | 11.37 | 9 | 34380 | 1021 | 50569714 |
Alopecia | 14.59 | 11.37 | 102 | 34287 | 244945 | 50325790 |
Cerebral haemorrhage | 14.59 | 11.37 | 46 | 34343 | 27006 | 50543729 |
Salpingo-oophorectomy bilateral | 14.57 | 11.37 | 5 | 34384 | 145 | 50570590 |
Coagulation factor V level decreased | 14.50 | 11.37 | 6 | 34383 | 294 | 50570441 |
Blood copper increased | 14.49 | 11.37 | 3 | 34386 | 10 | 50570725 |
Musculoskeletal chest pain | 14.47 | 11.37 | 36 | 34353 | 18450 | 50552285 |
Skin exfoliation | 14.47 | 11.37 | 53 | 34336 | 33559 | 50537176 |
Blood follicle stimulating hormone increased | 14.38 | 11.37 | 5 | 34384 | 151 | 50570584 |
Primary adrenal insufficiency | 14.32 | 11.37 | 4 | 34385 | 57 | 50570678 |
Breast cancer in situ | 14.28 | 11.37 | 10 | 34379 | 1421 | 50569314 |
Adenoid cystic carcinoma | 14.27 | 11.37 | 3 | 34386 | 11 | 50570724 |
Non-alcoholic steatohepatitis | 14.25 | 11.37 | 10 | 34379 | 1425 | 50569310 |
Injection site erythema | 14.22 | 11.37 | 18 | 34371 | 74918 | 50495817 |
Blood lactate dehydrogenase increased | 14.18 | 11.37 | 37 | 34352 | 19525 | 50551210 |
Trigger finger | 14.01 | 11.37 | 15 | 34374 | 3773 | 50566962 |
Atypical femur fracture | 14.00 | 11.37 | 17 | 34372 | 4899 | 50565836 |
Cardiomyopathy | 13.98 | 11.37 | 32 | 34357 | 15554 | 50555181 |
Ocular toxicity | 13.95 | 11.37 | 7 | 34382 | 538 | 50570197 |
Retinal artery occlusion | 13.93 | 11.37 | 10 | 34379 | 1477 | 50569258 |
Varices oesophageal | 13.93 | 11.37 | 13 | 34376 | 2776 | 50567959 |
Pelvic mass | 13.86 | 11.37 | 9 | 34380 | 1130 | 50569605 |
Encephalopathy | 13.82 | 11.37 | 3 | 34386 | 33708 | 50537027 |
Blister | 13.77 | 11.37 | 23 | 34366 | 85395 | 50485340 |
Multiple sclerosis relapse | 13.71 | 11.37 | 6 | 34383 | 42958 | 50527777 |
Hepatic cancer metastatic | 13.66 | 11.37 | 6 | 34383 | 341 | 50570394 |
Nasal congestion | 13.59 | 11.37 | 9 | 34380 | 51111 | 50519624 |
Oral mucosal hypertrophy | 13.52 | 11.37 | 3 | 34386 | 15 | 50570720 |
Diverticulitis | 13.50 | 11.37 | 3 | 34386 | 33179 | 50537556 |
Visual acuity reduced | 13.49 | 11.37 | 37 | 34352 | 20102 | 50550633 |
Postmenopausal haemorrhage | 13.46 | 11.37 | 11 | 34378 | 1969 | 50568766 |
Metastases to neck | 13.45 | 11.37 | 4 | 34385 | 72 | 50570663 |
Sepsis | 13.32 | 11.37 | 46 | 34343 | 132879 | 50437856 |
Papillary thyroid cancer | 13.29 | 11.37 | 11 | 34378 | 2004 | 50568731 |
Knee arthroplasty | 13.14 | 11.37 | 4 | 34385 | 35842 | 50534893 |
Corneal disorder | 13.13 | 11.37 | 10 | 34379 | 1616 | 50569119 |
Nasal dryness | 12.94 | 11.37 | 14 | 34375 | 3565 | 50567170 |
Madarosis | 12.92 | 11.37 | 12 | 34377 | 2548 | 50568187 |
Drug resistance | 12.83 | 11.37 | 35 | 34354 | 18954 | 50551781 |
Reversible cerebral vasoconstriction syndrome | 12.81 | 11.37 | 11 | 34378 | 2108 | 50568627 |
Oestradiol increased | 12.78 | 11.37 | 4 | 34385 | 86 | 50570649 |
Internal fixation of fracture | 12.66 | 11.37 | 7 | 34382 | 655 | 50570080 |
Hepatotoxicity | 12.63 | 11.37 | 44 | 34345 | 27182 | 50543553 |
Eosinophil count increased | 12.59 | 11.37 | 22 | 34367 | 8808 | 50561927 |
Myocardial infarction | 12.56 | 11.37 | 26 | 34363 | 89001 | 50481734 |
Lower limb fracture | 12.50 | 11.37 | 29 | 34360 | 14217 | 50556518 |
Neoplasm malignant | 12.49 | 11.37 | 40 | 34349 | 23675 | 50547060 |
Breast reconstruction | 12.48 | 11.37 | 5 | 34384 | 225 | 50570510 |
Desmoid tumour | 12.41 | 11.37 | 4 | 34385 | 95 | 50570640 |
Vein disorder | 12.41 | 11.37 | 15 | 34374 | 4304 | 50566431 |
Purulent discharge | 12.37 | 11.37 | 15 | 34374 | 4317 | 50566418 |
Alopecia areata | 12.36 | 11.37 | 9 | 34380 | 1359 | 50569376 |
Breast pain | 12.36 | 11.37 | 20 | 34369 | 7524 | 50563211 |
Metastases to adrenals | 12.36 | 11.37 | 7 | 34382 | 687 | 50570048 |
Retroperitoneal neoplasm metastatic | 12.31 | 11.37 | 3 | 34386 | 24 | 50570711 |
Abdominal pain upper | 12.30 | 11.37 | 61 | 34328 | 159248 | 50411487 |
Incorrect dose administered | 12.24 | 11.37 | 9 | 34380 | 48405 | 50522330 |
Superior sagittal sinus thrombosis | 12.23 | 11.37 | 7 | 34382 | 700 | 50570035 |
Pneumonia aspiration | 12.23 | 11.37 | 3 | 34386 | 31001 | 50539734 |
Dental caries | 12.06 | 11.37 | 23 | 34366 | 9844 | 50560891 |
Tooth disorder | 11.98 | 11.37 | 40 | 34349 | 24188 | 50546547 |
Influenza | 11.93 | 11.37 | 27 | 34362 | 89511 | 50481224 |
Endometrial adenocarcinoma | 11.88 | 11.37 | 8 | 34381 | 1067 | 50569668 |
Bile duct stenosis | 11.87 | 11.37 | 8 | 34381 | 1068 | 50569667 |
Hydronephrosis | 11.81 | 11.37 | 21 | 34368 | 8520 | 50562215 |
Injection site reaction | 11.77 | 11.37 | 10 | 34379 | 50022 | 50520713 |
Folliculitis | 11.71 | 11.37 | 6 | 34383 | 39219 | 50531516 |
Intestinal metastasis | 11.69 | 11.37 | 4 | 34385 | 115 | 50570620 |
Fungal disease carrier | 11.62 | 11.37 | 3 | 34386 | 31 | 50570704 |
Ovarian granulosa-theca cell tumour | 11.62 | 11.37 | 3 | 34386 | 31 | 50570704 |
HER2 gene amplification | 11.62 | 11.37 | 3 | 34386 | 31 | 50570704 |
Psoriatic arthropathy | 11.56 | 11.37 | 9 | 34380 | 47023 | 50523712 |
Glutamate dehydrogenase increased | 11.45 | 11.37 | 3 | 34386 | 33 | 50570702 |
Heart rate irregular | 11.44 | 11.37 | 34 | 34355 | 19326 | 50551409 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Metastases to bone | 81.86 | 28.34 | 25 | 1042 | 9873 | 29563587 |
Carbohydrate antigen 15-3 increased | 63.67 | 28.34 | 9 | 1058 | 69 | 29573391 |
Metastases to lung | 44.92 | 28.34 | 15 | 1052 | 7840 | 29565620 |
Metastases to central nervous system | 34.43 | 28.34 | 12 | 1055 | 7119 | 29566341 |
Malignant neoplasm progression | 33.87 | 28.34 | 25 | 1042 | 73834 | 29499626 |
Metastases to the mediastinum | 33.55 | 28.34 | 6 | 1061 | 223 | 29573237 |
PIK3CA-activated mutation | 31.19 | 28.34 | 5 | 1062 | 95 | 29573365 |
Hepatic lesion | 30.50 | 28.34 | 9 | 1058 | 3141 | 29570319 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Metastases to bone | 1150.36 | 12.26 | 401 | 26799 | 20034 | 64451498 |
Malignant neoplasm progression | 751.07 | 12.26 | 510 | 26690 | 112361 | 64359171 |
Metastases to liver | 496.82 | 12.26 | 229 | 26971 | 23712 | 64447820 |
Metastases to lung | 429.89 | 12.26 | 181 | 27019 | 15083 | 64456449 |
Metastases to lymph nodes | 348.26 | 12.26 | 133 | 27067 | 8584 | 64462948 |
Breast cancer metastatic | 310.34 | 12.26 | 116 | 27084 | 7053 | 64464479 |
Breast cancer recurrent | 308.52 | 12.26 | 90 | 27110 | 2493 | 64469039 |
Breast cancer | 220.51 | 12.26 | 143 | 27057 | 29005 | 64442527 |
Neoplasm progression | 211.57 | 12.26 | 159 | 27041 | 40805 | 64430727 |
Osteonecrosis of jaw | 189.00 | 12.26 | 147 | 27053 | 39678 | 64431854 |
Disease progression | 184.31 | 12.26 | 261 | 26939 | 141419 | 64330113 |
Metastases to central nervous system | 140.24 | 12.26 | 82 | 27118 | 13830 | 64457702 |
Metastases to spine | 136.25 | 12.26 | 53 | 27147 | 3590 | 64467942 |
Hot flush | 121.40 | 12.26 | 122 | 27078 | 46113 | 64425419 |
Bone lesion | 118.67 | 12.26 | 53 | 27147 | 5084 | 64466448 |
Sarcoma uterus | 116.72 | 12.26 | 18 | 27182 | 6 | 64471526 |
Tumour marker increased | 107.50 | 12.26 | 44 | 27156 | 3406 | 64468126 |
Osteonecrosis | 102.06 | 12.26 | 89 | 27111 | 28140 | 64443392 |
Second primary malignancy | 96.90 | 12.26 | 62 | 27138 | 12275 | 64459257 |
Acute myeloid leukaemia | 94.12 | 12.26 | 84 | 27116 | 27379 | 64444153 |
Metastases to skin | 91.29 | 12.26 | 31 | 27169 | 1421 | 64470111 |
Metastasis | 89.31 | 12.26 | 45 | 27155 | 5650 | 64465882 |
PIK3CA-activated mutation | 88.69 | 12.26 | 24 | 27176 | 501 | 64471031 |
Hepatic lesion | 88.35 | 12.26 | 45 | 27155 | 5779 | 64465753 |
Metastases to the mediastinum | 88.29 | 12.26 | 24 | 27176 | 510 | 64471022 |
Pseudocirrhosis | 83.80 | 12.26 | 24 | 27176 | 621 | 64470911 |
Endometrial cancer | 82.98 | 12.26 | 31 | 27169 | 1879 | 64469653 |
Endometrial hyperplasia | 80.29 | 12.26 | 22 | 27178 | 482 | 64471050 |
Neuropathy peripheral | 79.66 | 12.26 | 162 | 27038 | 117363 | 64354169 |
Uterine polyp | 78.33 | 12.26 | 27 | 27173 | 1295 | 64470237 |
Carbohydrate antigen 15-3 increased | 77.81 | 12.26 | 25 | 27175 | 962 | 64470570 |
Bone disorder | 77.60 | 12.26 | 61 | 27139 | 16698 | 64454834 |
Breast mass | 77.57 | 12.26 | 40 | 27160 | 5270 | 64466262 |
Tonsillar disorder | 77.47 | 12.26 | 25 | 27175 | 976 | 64470556 |
Metastases to pleura | 71.75 | 12.26 | 25 | 27175 | 1239 | 64470293 |
Endometrial atrophy | 71.34 | 12.26 | 13 | 27187 | 34 | 64471498 |
Lymphadenopathy | 66.56 | 12.26 | 90 | 27110 | 46596 | 64424936 |
Device related thrombosis | 66.35 | 12.26 | 27 | 27173 | 2058 | 64469474 |
Nasal disorder | 64.21 | 12.26 | 29 | 27171 | 2855 | 64468677 |
Osteolysis | 61.81 | 12.26 | 28 | 27172 | 2775 | 64468757 |
Hormone receptor positive breast cancer | 60.65 | 12.26 | 16 | 27184 | 302 | 64471230 |
Blood uric acid decreased | 59.43 | 12.26 | 21 | 27179 | 1085 | 64470447 |
Acute promyelocytic leukaemia | 58.38 | 12.26 | 22 | 27178 | 1366 | 64470166 |
Nail disorder | 57.19 | 12.26 | 39 | 27161 | 8585 | 64462947 |
Bone pain | 56.43 | 12.26 | 84 | 27116 | 47488 | 64424044 |
Eosinophil percentage increased | 54.25 | 12.26 | 21 | 27179 | 1403 | 64470129 |
Completed suicide | 54.00 | 12.26 | 14 | 27186 | 224400 | 64247132 |
Lymphoedema | 52.32 | 12.26 | 39 | 27161 | 9866 | 64461666 |
Recurrent cancer | 50.11 | 12.26 | 23 | 27177 | 2350 | 64469182 |
Metastases to chest wall | 48.35 | 12.26 | 14 | 27186 | 377 | 64471155 |
Metastases to pelvis | 48.10 | 12.26 | 15 | 27185 | 523 | 64471009 |
Disease recurrence | 46.83 | 12.26 | 62 | 27138 | 31448 | 64440084 |
Pulmonary mass | 46.54 | 12.26 | 54 | 27146 | 23962 | 64447570 |
Recall phenomenon | 46.17 | 12.26 | 17 | 27183 | 989 | 64470543 |
Lymphangiosis carcinomatosa | 45.97 | 12.26 | 20 | 27180 | 1801 | 64469731 |
Excessive eye blinking | 45.95 | 12.26 | 18 | 27182 | 1242 | 64470290 |
Vitreous detachment | 44.72 | 12.26 | 20 | 27180 | 1924 | 64469608 |
Endometrial hypertrophy | 44.50 | 12.26 | 11 | 27189 | 158 | 64471374 |
Metastases to peritoneum | 44.11 | 12.26 | 24 | 27176 | 3523 | 64468009 |
Breast cancer female | 43.46 | 12.26 | 27 | 27173 | 5076 | 64466456 |
Cerebral venous thrombosis | 43.36 | 12.26 | 21 | 27179 | 2420 | 64469112 |
Lymphadenopathy mediastinal | 42.12 | 12.26 | 24 | 27176 | 3852 | 64467680 |
Bronchomalacia | 41.53 | 12.26 | 11 | 27189 | 211 | 64471321 |
Peritoneal disorder | 41.36 | 12.26 | 14 | 27186 | 635 | 64470897 |
Left ventricular dilatation | 40.03 | 12.26 | 15 | 27185 | 917 | 64470615 |
Uterine cancer | 39.95 | 12.26 | 21 | 27179 | 2877 | 64468655 |
Retinopathy | 39.73 | 12.26 | 22 | 27178 | 3343 | 64468189 |
Metastases to ovary | 39.72 | 12.26 | 11 | 27189 | 251 | 64471281 |
Invasive ductal breast carcinoma | 38.75 | 12.26 | 25 | 27175 | 5017 | 64466515 |
Adnexa uteri mass | 38.39 | 12.26 | 11 | 27189 | 285 | 64471247 |
Pulmonary embolism | 38.16 | 12.26 | 142 | 27058 | 146214 | 64325318 |
Pneumonia | 37.87 | 12.26 | 116 | 27084 | 559460 | 63912072 |
Endometrial thickening | 37.84 | 12.26 | 10 | 27190 | 190 | 64471342 |
Endometriosis | 37.83 | 12.26 | 20 | 27180 | 2772 | 64468760 |
Joint swelling | 37.72 | 12.26 | 22 | 27178 | 215360 | 64256172 |
Ovarian cancer | 37.28 | 12.26 | 21 | 27179 | 3298 | 64468234 |
Drug ineffective | 35.93 | 12.26 | 208 | 26992 | 840039 | 63631493 |
Haematotoxicity | 35.62 | 12.26 | 35 | 27165 | 12861 | 64458671 |
Vulvovaginal dryness | 35.26 | 12.26 | 16 | 27184 | 1592 | 64469940 |
Maculopathy | 34.16 | 12.26 | 18 | 27182 | 2478 | 64469054 |
Menopausal disorder | 34.09 | 12.26 | 7 | 27193 | 40 | 64471492 |
Acute kidney injury | 33.40 | 12.26 | 89 | 27111 | 449151 | 64022381 |
Palmar-plantar erythrodysaesthesia syndrome | 32.90 | 12.26 | 50 | 27150 | 28769 | 64442763 |
Uterine leiomyoma | 32.59 | 12.26 | 23 | 27177 | 5346 | 64466186 |
Pleural disorder | 32.24 | 12.26 | 12 | 27188 | 720 | 64470812 |
Tooth extraction | 32.16 | 12.26 | 29 | 27171 | 9572 | 64461960 |
Hypertriglyceridaemia | 32.05 | 12.26 | 31 | 27169 | 11174 | 64460358 |
Metastases to eye | 32.03 | 12.26 | 9 | 27191 | 217 | 64471315 |
Pathological fracture | 31.75 | 12.26 | 28 | 27172 | 8977 | 64462555 |
Pleural effusion | 31.50 | 12.26 | 121 | 27079 | 126438 | 64345094 |
Menopause | 31.27 | 12.26 | 15 | 27185 | 1693 | 64469839 |
Blood creatinine decreased | 31.21 | 12.26 | 25 | 27175 | 7025 | 64464507 |
Neutropenia | 31.16 | 12.26 | 190 | 27010 | 239434 | 64232098 |
Ejection fraction decreased | 30.25 | 12.26 | 48 | 27152 | 28659 | 64442873 |
Rheumatoid arthritis | 29.89 | 12.26 | 16 | 27184 | 164278 | 64307254 |
Osteitis condensans | 29.73 | 12.26 | 6 | 27194 | 31 | 64471501 |
Contraindicated product administered | 29.47 | 12.26 | 5 | 27195 | 107824 | 64363708 |
Radiation pneumonitis | 29.33 | 12.26 | 18 | 27182 | 3310 | 64468222 |
Metastases to thorax | 29.30 | 12.26 | 8 | 27192 | 173 | 64471359 |
Tympanic membrane disorder | 29.21 | 12.26 | 8 | 27192 | 175 | 64471357 |
Ascites | 29.17 | 12.26 | 74 | 27126 | 61927 | 64409605 |
Radiation necrosis | 28.61 | 12.26 | 9 | 27191 | 323 | 64471209 |
Therapeutic product effect decreased | 28.11 | 12.26 | 7 | 27193 | 115344 | 64356188 |
Toxicity to various agents | 27.77 | 12.26 | 71 | 27129 | 363442 | 64108090 |
Cardiac cirrhosis | 27.75 | 12.26 | 8 | 27192 | 212 | 64471320 |
Tumour marker decreased | 27.69 | 12.26 | 6 | 27194 | 46 | 64471486 |
Portal hypertension | 27.42 | 12.26 | 22 | 27178 | 6197 | 64465335 |
Metastases to uterus | 26.64 | 12.26 | 6 | 27194 | 56 | 64471476 |
Hypertransaminasaemia | 26.64 | 12.26 | 23 | 27177 | 7168 | 64464364 |
Atrophic vulvovaginitis | 26.49 | 12.26 | 12 | 27188 | 1189 | 64470343 |
Menopausal symptoms | 26.21 | 12.26 | 13 | 27187 | 1577 | 64469955 |
Synovitis | 26.20 | 12.26 | 5 | 27195 | 99085 | 64372447 |
Exposed bone in jaw | 26.08 | 12.26 | 17 | 27183 | 3470 | 64468062 |
Malignant pleural effusion | 26.03 | 12.26 | 16 | 27184 | 2951 | 64468581 |
Deprescribing error | 25.25 | 12.26 | 5 | 27195 | 23 | 64471509 |
Mucosal toxicity | 25.14 | 12.26 | 9 | 27191 | 483 | 64471049 |
Hepatic cirrhosis | 25.04 | 12.26 | 42 | 27158 | 26256 | 64445276 |
Hepatic steatosis | 24.96 | 12.26 | 46 | 27154 | 30961 | 64440571 |
Left ventricular dysfunction | 24.63 | 12.26 | 33 | 27167 | 16921 | 64454611 |
Metastatic neoplasm | 24.61 | 12.26 | 18 | 27182 | 4424 | 64467108 |
Sepsis | 24.49 | 12.26 | 37 | 27163 | 230304 | 64241228 |
Fibrous histiocytoma | 24.34 | 12.26 | 9 | 27191 | 530 | 64471002 |
Vaginal haemorrhage | 24.15 | 12.26 | 35 | 27165 | 19309 | 64452223 |
Gastrointestinal haemorrhage | 23.89 | 12.26 | 13 | 27187 | 132299 | 64339233 |
Lower limb fracture | 23.84 | 12.26 | 29 | 27171 | 13516 | 64458016 |
Gastrointestinal toxicity | 23.83 | 12.26 | 19 | 27181 | 5303 | 64466229 |
Sequestrectomy | 23.66 | 12.26 | 10 | 27190 | 839 | 64470693 |
Disturbance in attention | 23.62 | 12.26 | 53 | 27147 | 41021 | 64430511 |
Breast cancer in situ | 23.40 | 12.26 | 10 | 27190 | 862 | 64470670 |
Paraesthesia | 23.06 | 12.26 | 115 | 27085 | 134407 | 64337125 |
Septic shock | 22.77 | 12.26 | 8 | 27192 | 105429 | 64366103 |
RET gene mutation | 22.70 | 12.26 | 4 | 27196 | 8 | 64471524 |
Systemic lupus erythematosus | 22.58 | 12.26 | 3 | 27197 | 77609 | 64393923 |
Myocardial infarction | 22.53 | 12.26 | 22 | 27178 | 165799 | 64305733 |
Injection site extravasation | 22.43 | 12.26 | 22 | 27178 | 8064 | 64463468 |
Radiation skin injury | 22.30 | 12.26 | 11 | 27189 | 1319 | 64470213 |
Hypotension | 22.30 | 12.26 | 84 | 27116 | 380890 | 64090642 |
Cervical polyp | 22.14 | 12.26 | 6 | 27194 | 126 | 64471406 |
Adenomyosis | 21.92 | 12.26 | 7 | 27193 | 264 | 64471268 |
Porphyria non-acute | 21.80 | 12.26 | 9 | 27191 | 712 | 64470820 |
Invasive breast carcinoma | 21.72 | 12.26 | 8 | 27192 | 466 | 64471066 |
Gingival bleeding | 21.72 | 12.26 | 29 | 27171 | 14825 | 64456707 |
Therapy partial responder | 21.47 | 12.26 | 24 | 27176 | 10224 | 64461308 |
Cardiotoxicity | 21.43 | 12.26 | 24 | 27176 | 10250 | 64461282 |
Lymphangioleiomyomatosis | 21.42 | 12.26 | 6 | 27194 | 143 | 64471389 |
Osteosclerosis | 21.31 | 12.26 | 15 | 27185 | 3471 | 64468061 |
Abdominal lymphadenopathy | 20.95 | 12.26 | 10 | 27190 | 1116 | 64470416 |
Toothache | 20.94 | 12.26 | 31 | 27169 | 17428 | 64454104 |
Invasive lobular breast carcinoma | 20.63 | 12.26 | 8 | 27192 | 537 | 64470995 |
Leiomyoma | 20.57 | 12.26 | 7 | 27193 | 323 | 64471209 |
Arteriovenous malformation | 20.54 | 12.26 | 11 | 27189 | 1565 | 64469967 |
Amenorrhoea | 20.43 | 12.26 | 19 | 27181 | 6520 | 64465012 |
Hepatic enzyme increased | 20.39 | 12.26 | 15 | 27185 | 129928 | 64341604 |
Onycholysis | 20.22 | 12.26 | 11 | 27189 | 1615 | 64469917 |
Oestradiol abnormal | 20.10 | 12.26 | 4 | 27196 | 19 | 64471513 |
Tumour invasion | 20.07 | 12.26 | 7 | 27193 | 348 | 64471184 |
Sensory loss | 19.93 | 12.26 | 23 | 27177 | 10146 | 64461386 |
Breast disorder | 19.85 | 12.26 | 11 | 27189 | 1673 | 64469859 |
Atypical femur fracture | 19.41 | 12.26 | 16 | 27184 | 4682 | 64466850 |
Metastases to meninges | 19.30 | 12.26 | 13 | 27187 | 2802 | 64468730 |
Ovarian hyperstimulation syndrome | 19.18 | 12.26 | 13 | 27187 | 2832 | 64468700 |
Superior sagittal sinus thrombosis | 19.18 | 12.26 | 9 | 27191 | 967 | 64470565 |
Meningeal disorder | 19.03 | 12.26 | 7 | 27193 | 406 | 64471126 |
Madarosis | 19.01 | 12.26 | 12 | 27188 | 2318 | 64469214 |
Postmenopausal haemorrhage | 18.66 | 12.26 | 10 | 27190 | 1425 | 64470107 |
Drug abuse | 18.64 | 12.26 | 17 | 27183 | 132357 | 64339175 |
Cortisol increased | 18.58 | 12.26 | 7 | 27193 | 434 | 64471098 |
Vertebral lesion | 18.54 | 12.26 | 7 | 27193 | 437 | 64471095 |
Ovarian cyst | 18.44 | 12.26 | 23 | 27177 | 10995 | 64460537 |
Deafness | 18.39 | 12.26 | 30 | 27170 | 18329 | 64453203 |
Multiple organ dysfunction syndrome | 18.26 | 12.26 | 10 | 27190 | 101403 | 64370129 |
Metastases to stomach | 18.17 | 12.26 | 6 | 27194 | 252 | 64471280 |
Polyneuropathy | 17.92 | 12.26 | 31 | 27169 | 19863 | 64451669 |
Respiratory tract inflammation | 17.76 | 12.26 | 8 | 27192 | 782 | 64470750 |
Glossodynia | 17.67 | 12.26 | 3 | 27197 | 64693 | 64406839 |
Corneal degeneration | 17.66 | 12.26 | 5 | 27195 | 124 | 64471408 |
Bone sequestrum | 17.61 | 12.26 | 9 | 27191 | 1163 | 64470369 |
Pain in jaw | 17.49 | 12.26 | 47 | 27153 | 40708 | 64430824 |
Oxygen saturation decreased | 17.30 | 12.26 | 12 | 27188 | 107164 | 64364368 |
Acarodermatitis | 17.19 | 12.26 | 9 | 27191 | 1223 | 64470309 |
Breast neoplasm | 17.15 | 12.26 | 8 | 27192 | 848 | 64470684 |
Central nervous system lesion | 17.12 | 12.26 | 23 | 27177 | 11826 | 64459706 |
Eastern Cooperative Oncology Group performance status worsened | 17.08 | 12.26 | 9 | 27191 | 1239 | 64470293 |
Hydrothorax | 17.02 | 12.26 | 9 | 27191 | 1248 | 64470284 |
Liver scan abnormal | 16.77 | 12.26 | 4 | 27196 | 49 | 64471483 |
Nasal dryness | 16.68 | 12.26 | 13 | 27187 | 3513 | 64468019 |
Paraneoplastic syndrome | 16.66 | 12.26 | 8 | 27192 | 905 | 64470627 |
Trigger finger | 16.61 | 12.26 | 13 | 27187 | 3532 | 64468000 |
Reversible cerebral vasoconstriction syndrome | 16.50 | 12.26 | 11 | 27189 | 2331 | 64469201 |
Corneal graft rejection | 16.48 | 12.26 | 4 | 27196 | 53 | 64471479 |
Treatment failure | 16.45 | 12.26 | 15 | 27185 | 116801 | 64354731 |
Actinomycosis | 16.42 | 12.26 | 8 | 27192 | 934 | 64470598 |
Neutrophilia | 16.35 | 12.26 | 17 | 27183 | 6677 | 64464855 |
Hair texture abnormal | 16.25 | 12.26 | 12 | 27188 | 2992 | 64468540 |
Intermenstrual bleeding | 16.23 | 12.26 | 15 | 27185 | 5110 | 64466422 |
Wound | 16.17 | 12.26 | 6 | 27194 | 76471 | 64395061 |
Metabolic acidosis | 15.99 | 12.26 | 5 | 27195 | 70953 | 64400579 |
Cardio-respiratory arrest | 15.91 | 12.26 | 11 | 27189 | 98382 | 64373150 |
Non-alcoholic steatohepatitis | 15.80 | 12.26 | 10 | 27190 | 1942 | 64469590 |
Rapidly progressive osteoarthritis | 15.70 | 12.26 | 3 | 27197 | 11 | 64471521 |
Haemangioma of liver | 15.53 | 12.26 | 8 | 27192 | 1052 | 64470480 |
Corneal disorder | 15.45 | 12.26 | 10 | 27190 | 2017 | 64469515 |
Breath odour | 15.40 | 12.26 | 9 | 27191 | 1515 | 64470017 |
Alopecia areata | 15.38 | 12.26 | 9 | 27191 | 1519 | 64470013 |
Diabetic hyperosmolar coma | 15.31 | 12.26 | 7 | 27193 | 709 | 64470823 |
BRCA2 gene mutation | 15.29 | 12.26 | 4 | 27196 | 73 | 64471459 |
Hypersensitivity | 15.27 | 12.26 | 38 | 27162 | 196414 | 64275118 |
Respiratory tract oedema | 15.18 | 12.26 | 7 | 27193 | 723 | 64470809 |
Adenocarcinoma | 15.08 | 12.26 | 12 | 27188 | 3339 | 64468193 |
Jaw operation | 14.92 | 12.26 | 7 | 27193 | 752 | 64470780 |
Spinal cord compression | 14.87 | 12.26 | 15 | 27185 | 5688 | 64465844 |
Debridement | 14.86 | 12.26 | 9 | 27191 | 1617 | 64469915 |
Hysteroscopy | 14.78 | 12.26 | 3 | 27197 | 16 | 64471516 |
Oral mucosal hypertrophy | 14.78 | 12.26 | 3 | 27197 | 16 | 64471516 |
Breast reconstruction | 14.67 | 12.26 | 4 | 27196 | 86 | 64471446 |
Portal vein thrombosis | 14.64 | 12.26 | 14 | 27186 | 4977 | 64466555 |
Adenoid cystic carcinoma | 14.63 | 12.26 | 3 | 27197 | 17 | 64471515 |
Central nervous system infection | 14.63 | 12.26 | 8 | 27192 | 1186 | 64470346 |
Metastases to breast | 14.50 | 12.26 | 5 | 27195 | 240 | 64471292 |
Retinal artery occlusion | 14.38 | 12.26 | 11 | 27189 | 2892 | 64468640 |
Encapsulating peritoneal sclerosis | 14.36 | 12.26 | 7 | 27193 | 818 | 64470714 |
Oestradiol increased | 14.33 | 12.26 | 4 | 27196 | 94 | 64471438 |
Respiratory failure | 14.30 | 12.26 | 29 | 27171 | 161154 | 64310378 |
Cystoid macular oedema | 14.14 | 12.26 | 9 | 27191 | 1765 | 64469767 |
Dyspareunia | 14.12 | 12.26 | 9 | 27191 | 1768 | 64469764 |
Chronic hepatic failure | 14.09 | 12.26 | 7 | 27193 | 852 | 64470680 |
Sinusitis | 14.04 | 12.26 | 25 | 27175 | 145903 | 64325629 |
Hair colour changes | 13.97 | 12.26 | 12 | 27188 | 3715 | 64467817 |
Neoplasm recurrence | 13.93 | 12.26 | 12 | 27188 | 3727 | 64467805 |
Atrial thrombosis | 13.92 | 12.26 | 11 | 27189 | 3031 | 64468501 |
Back pain | 13.91 | 12.26 | 164 | 27036 | 250007 | 64221525 |
Coma | 13.89 | 12.26 | 10 | 27190 | 87605 | 64383927 |
Breast pain | 13.88 | 12.26 | 16 | 27184 | 7045 | 64464487 |
Performance status decreased | 13.78 | 12.26 | 14 | 27186 | 5350 | 64466182 |
Carcinoembryonic antigen increased | 13.69 | 12.26 | 9 | 27191 | 1864 | 64469668 |
Pneumonia aspiration | 13.67 | 12.26 | 4 | 27196 | 59267 | 64412265 |
Endometrial adenocarcinoma | 13.55 | 12.26 | 7 | 27193 | 925 | 64470607 |
Encephalopathy | 13.51 | 12.26 | 4 | 27196 | 58815 | 64412717 |
Dental operation | 13.41 | 12.26 | 7 | 27193 | 945 | 64470587 |
Intentional overdose | 13.33 | 12.26 | 11 | 27189 | 89933 | 64381599 |
Ovarian granulosa-theca cell tumour | 13.32 | 12.26 | 3 | 27197 | 28 | 64471504 |
Mucosal inflammation | 13.30 | 12.26 | 57 | 27143 | 62527 | 64409005 |
Femur fracture | 13.29 | 12.26 | 38 | 27162 | 34097 | 64437435 |
Coagulation factor V level decreased | 13.26 | 12.26 | 6 | 27194 | 593 | 64470939 |
Metastases to muscle | 13.11 | 12.26 | 5 | 27195 | 321 | 64471211 |
Skin exfoliation | 12.91 | 12.26 | 45 | 27155 | 44840 | 64426692 |
Aeromonas infection | 12.89 | 12.26 | 5 | 27195 | 336 | 64471196 |
Product use issue | 12.87 | 12.26 | 28 | 27172 | 151687 | 64319845 |
Abdominal discomfort | 12.85 | 12.26 | 37 | 27163 | 182285 | 64289247 |
Gingivitis | 12.84 | 12.26 | 16 | 27184 | 7643 | 64463889 |
Ocular toxicity | 12.83 | 12.26 | 6 | 27194 | 640 | 64470892 |
Atypical fracture | 12.74 | 12.26 | 6 | 27194 | 650 | 64470882 |
Cardiomyopathy | 12.70 | 12.26 | 31 | 27169 | 25325 | 64446207 |
Ventricular hypokinesia | 12.65 | 12.26 | 16 | 27184 | 7753 | 64463779 |
Rhabdomyolysis | 12.65 | 12.26 | 12 | 27188 | 91714 | 64379818 |
Rhabdomyosarcoma | 12.63 | 12.26 | 4 | 27196 | 147 | 64471385 |
Unresponsive to stimuli | 12.38 | 12.26 | 3 | 27197 | 50390 | 64421142 |
Neoplasm | 12.29 | 12.26 | 15 | 27185 | 7016 | 64464516 |
None
Source | Code | Description |
---|---|---|
ATC | L02BA01 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONE ANTAGONISTS AND RELATED AGENTS Anti-estrogens |
FDA MoA | N0000000168 | Selective Estrogen Receptor Modulators |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D018931 | Antineoplastic Agents, Hormonal |
MeSH PA | D050071 | Bone Density Conservation Agents |
MeSH PA | D004965 | Estrogen Antagonists |
MeSH PA | D020847 | Estrogen Receptor Modulators |
MeSH PA | D006727 | Hormone Antagonists |
MeSH PA | D020845 | Selective Estrogen Receptor Modulators |
FDA EPC | N0000175826 | Estrogen Agonist/Antagonist |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:37700 | protein kinase C inhibitors |
CHEBI has role | CHEBI:48422 | angiogenesis antagonist |
CHEBI has role | CHEBI:50646 | antiosteoporotic |
CHEBI has role | CHEBI:50792 | estrogen receptor antagonists |
CHEBI has role | CHEBI:50837 | oestrogen antagonist |
CHEBI has role | CHEBI:62872 | quinoline oxidase inhibitors |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Infiltrating duct carcinoma of breast | indication | 408643008 | DOID:3008 |
Carcinoma of female breast | indication | 447782002 | |
Prevention of Breast Carcinoma | indication | ||
Pain of breast | off-label use | 53430007 | |
Endometrial carcinoma | off-label use | 254878006 | DOID:2871 |
Malignant tumor of ovary | off-label use | 363443007 | DOID:2394 |
Hypercalcemia | contraindication | 66931009 | DOID:12678 |
Leukopenia | contraindication | 84828003 | DOID:615 |
Bilateral cataracts | contraindication | 95722004 | |
Deep venous thrombosis | contraindication | 128053003 | |
Cerebrovascular accident | contraindication | 230690007 | |
Pulmonary thromboembolism | contraindication | 233935004 | |
Pregnancy, function | contraindication | 289908002 | |
Thrombocytopenic disorder | contraindication | 302215000 | DOID:1588 |
Thromboembolic disorder | contraindication | 371039008 | |
Visual impairment | contraindication | 397540003 | |
Breastfeeding (mother) | contraindication | 413712001 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 8.61 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Estrogen receptor | Nuclear hormone receptor | MODULATOR | Ki | 7.51 | CHEMBL | CHEMBL | |||
Beta-1 adrenergic receptor | GPCR | Ki | 5.00 | DRUG MATRIX | |||||
Prostaglandin G/H synthase 2 | Enzyme | IC50 | 4.46 | WOMBAT-PK | |||||
Prostaglandin G/H synthase 1 | Enzyme | IC50 | 5.36 | DRUG MATRIX | |||||
Mu-type opioid receptor | GPCR | Ki | 5.15 | DRUG MATRIX | |||||
D(1A) dopamine receptor | GPCR | Ki | 5.37 | DRUG MATRIX | |||||
D(2) dopamine receptor | GPCR | Ki | 5.34 | DRUG MATRIX | |||||
Estrogen-related receptor gamma | Nuclear hormone receptor | Ki | 7.10 | WOMBAT-PK | |||||
Adenosine receptor A2a | GPCR | Ki | 5.40 | DRUG MATRIX | |||||
Alpha-2A adrenergic receptor | GPCR | Ki | 6.14 | DRUG MATRIX | |||||
Sigma non-opioid intracellular receptor 1 | Membrane receptor | Ki | 7.50 | WOMBAT-PK | |||||
Potassium voltage-gated channel subfamily H member 2 | Ion channel | IC50 | 5.80 | CHEMBL | |||||
3-beta-hydroxysteroid-Delta(8),Delta(7)-isomerase | Enzyme | Ki | 8.30 | WOMBAT-PK | |||||
Multidrug resistance protein 1 | Transporter | Ki | 7 | WOMBAT-PK | |||||
Sodium-dependent serotonin transporter | Transporter | Ki | 5.91 | DRUG MATRIX | |||||
Sodium-dependent noradrenaline transporter | Transporter | Ki | 5.84 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 1A | GPCR | Ki | 5.16 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2A | GPCR | Ki | 5.86 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2B | GPCR | Ki | 5.88 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 2C | GPCR | Ki | 6.62 | DRUG MATRIX | |||||
5-hydroxytryptamine receptor 6 | GPCR | Ki | 5.98 | CHEMBL | |||||
Alpha-2B adrenergic receptor | GPCR | Ki | 5.79 | DRUG MATRIX | |||||
D(3) dopamine receptor | GPCR | Ki | 6.44 | DRUG MATRIX | |||||
Histamine H2 receptor | GPCR | Ki | 5.03 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M1 | GPCR | Ki | 6.17 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M2 | GPCR | Ki | 5.56 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M3 | GPCR | Ki | 6.20 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M4 | GPCR | Ki | 6.17 | DRUG MATRIX | |||||
Muscarinic acetylcholine receptor M5 | GPCR | Ki | 5.73 | DRUG MATRIX | |||||
Aldehyde oxidase | Enzyme | IC50 | 5.66 | WOMBAT-PK | |||||
Beta-3 adrenergic receptor | GPCR | Ki | 5.24 | DRUG MATRIX | |||||
Sodium-dependent dopamine transporter | Transporter | Ki | 5.84 | DRUG MATRIX | |||||
Adenosine receptor A1 | GPCR | Ki | 4.86 | DRUG MATRIX | |||||
Adenosine receptor A3 | GPCR | Ki | 5.68 | DRUG MATRIX | |||||
Nuclear receptor subfamily 1 group I member 2 | Nuclear hormone receptor | Ki | 7.46 | WOMBAT-PK | |||||
D(4) dopamine receptor | GPCR | Ki | 5.41 | DRUG MATRIX | |||||
Alpha-1D adrenergic receptor | GPCR | Ki | 5.61 | DRUG MATRIX | |||||
Kappa-type opioid receptor | GPCR | Ki | 5.20 | DRUG MATRIX | |||||
Progesterone receptor | Nuclear hormone receptor | IC50 | 6.89 | CHEMBL | |||||
Delta-type opioid receptor | GPCR | Ki | 5.33 | DRUG MATRIX | |||||
Estrogen receptor beta | Nuclear hormone receptor | IC50 | 5.91 | WOMBAT-PK | |||||
G-protein coupled estrogen receptor 1 | GPCR | IC50 | 7.50 | WOMBAT-PK | |||||
Epidermal growth factor receptor | Kinase | IC50 | 5.45 | DRUG MATRIX | |||||
Substance-P receptor | GPCR | Ki | 5.07 | DRUG MATRIX | |||||
Tyrosine-protein kinase Lck | Kinase | IC50 | 5.10 | DRUG MATRIX | |||||
Tyrosine-protein kinase Fyn | Kinase | IC50 | 5.92 | DRUG MATRIX | |||||
Receptor tyrosine-protein kinase erbB-2 | Kinase | IC50 | 5.53 | DRUG MATRIX | |||||
Glucosylceramidase | Enzyme | EC50 | 5.60 | CHEMBL | |||||
Thromboxane-A synthase | Enzyme | IC50 | 6.04 | DRUG MATRIX | |||||
Steroid hormone receptor ERR1 | Nuclear hormone receptor | IC50 | 6.70 | CHEMBL | |||||
Substance-K receptor | GPCR | Ki | 5.91 | DRUG MATRIX | |||||
B2 bradykinin receptor | GPCR | Ki | 4.92 | DRUG MATRIX | |||||
Melanocortin receptor 4 | GPCR | Ki | 4.53 | DRUG MATRIX | |||||
Melanocortin receptor 5 | GPCR | Ki | 4.60 | DRUG MATRIX | |||||
Melanocortin receptor 3 | GPCR | Ki | 4.76 | DRUG MATRIX | |||||
Serine/threonine-protein phosphatase 2B catalytic subunit alpha isoform | Enzyme | IC50 | 4.52 | DRUG MATRIX | |||||
Solute carrier family 22 member 2 | Transporter | IC50 | 4.06 | WOMBAT-PK | |||||
Emopamil-binding protein-like | Enzyme | Ki | 8.55 | CHEMBL | |||||
Anti-estrogen binding site (AEBS) | Enzyme | Kd | 9 | CHEMBL | |||||
Androgen receptor | Transcription factor | Ki | 4.82 | DRUG MATRIX | |||||
Membrane-associated progesterone receptor component 1 | Membrane receptor | Ki | 6.42 | DRUG MATRIX | |||||
Progesterone receptor | Transcription factor | Ki | 5.59 | DRUG MATRIX | |||||
Alpha-1A adrenergic receptor | GPCR | IC50 | 4.66 | CHEMBL | |||||
5-hydroxytryptamine receptor 1A | GPCR | IC50 | 4.92 | CHEMBL | |||||
C-8 sterol isomerase | Enzyme | Ki | 5.82 | CHEMBL | |||||
Sodium/potassium-transporting ATPase subunit alpha-2 | Ion channel | IC50 | 4.81 | DRUG MATRIX | |||||
Transcriptional activator protein luxR | Unclassified | IC50 | 4.40 | CHEMBL |
ID | Source |
---|---|
4019939 | VUID |
N0000148024 | NUI |
D00966 | KEGG_DRUG |
54965-24-1 | SECONDARY_CAS_RN |
4018462 | VANDF |
4019939 | VANDF |
C0039286 | UMLSCUI |
CHEBI:41774 | CHEBI |
CTX | PDB_CHEM_ID |
CHEMBL83 | ChEMBL_ID |
DB00675 | DRUGBANK_ID |
CHEMBL786 | ChEMBL_ID |
D013629 | MESH_DESCRIPTOR_UI |
2733526 | PUBCHEM_CID |
1016 | IUPHAR_LIGAND_ID |
3299 | INN_ID |
094ZI81Y45 | UNII |
10324 | RXNORM |
2281 | MMSL |
4270 | MMSL |
5540 | MMSL |
d00381 | MMSL |
002670 | NDDF |
004826 | NDDF |
373345002 | SNOMEDCT_US |
41395001 | SNOMEDCT_US |
75959001 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0144 | TABLET | 10 mg | ORAL | ANDA | 26 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0378-0274 | TABLET | 20 mg | ORAL | ANDA | 26 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2472 | TABLET | 10 mg | ORAL | ANDA | 25 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2472 | TABLET | 10 mg | ORAL | ANDA | 25 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2473 | TABLET | 20 mg | ORAL | ANDA | 25 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0591-2473 | TABLET | 20 mg | ORAL | ANDA | 25 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0485 | TABLET | 10 mg | ORAL | ANDA | 25 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50090-0942 | TABLET | 20 mg | ORAL | ANDA | 25 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-439 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 28 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-439 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 28 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-440 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 28 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51407-440 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 28 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-446 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 26 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-447 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 26 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-642 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 28 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-642 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 28 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-643 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 28 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-643 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 28 sections |
SOLTAMOX | HUMAN PRESCRIPTION DRUG LABEL | 1 | 51862-682 | LIQUID | 20 mg | ORAL | NDA | 33 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-3004 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 26 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54868-4287 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 26 sections |
Tamoxifen Citrate | Human Prescription Drug Label | 1 | 59651-299 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 24 sections |
Tamoxifen Citrate | Human Prescription Drug Label | 1 | 59651-300 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 24 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-909 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 26 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-909 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 26 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-910 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 26 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60429-910 | TABLET, FILM COATED | 20 mg | ORAL | ANDA | 26 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63187-976 | TABLET | 20 mg | ORAL | ANDA | 25 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63739-143 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 28 sections |
Tamoxifen Citrate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63739-269 | TABLET, FILM COATED | 10 mg | ORAL | ANDA | 26 sections |